Aurinia Pharmaceuticals Inc. (TSE:AUP), a biopharma stock, moved higher after announcing additional lupus nephritis study results
Sean Mason | April 21, 2017 | SmallCapPower
Promising lupus nephritis drug study results sparked investor interest in a biopharma stock Friday. Here’s some small stocks making big moves on Friday, April 21, 2017 (as of 4 pm EST):
Biopharma stock Aurinia Pharmaceuticals Inc. (TSX: AUP) gained 2% to $9.61 on Friday after announcing additional 48-week results from its global Phase IIb AURA-LV (AURA) study in lupus nephritis during the National Kidney Foundation 2017 Spring Clinical Meetings, which the Company said showed continued improvements in renal and extra-renal outcomes.
As well, shares of Energizer Resources Inc. (TSX: EGZ) climbed as much as 10% before ending unchanged at $0.10 as the graphite junior said it has revised Phase 1 of its mine development plan for its 100%-owned Molo Graphite Project in Madagascar to now include significant production and added that the completion of an updated Feasibility Study to reflect this development is imminent.
Home Capital Group Inc. (TSX: HCG), meanwhile, reported that it expects to earn $0.90 a share in its first-quarter and $1.02 on an adjusted diluted basis. This compares with $0.92 and $0.96, respectively, during the same period last year. Home Capital Group stock moved up 9% to $19.25 following the announcement.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: